Background Chronic kidney disease is an important cause of global mortality and morbidity. Data for epidemiological features of chronic kidney disease and its risk factors are limited for low-income and middle-income countries. The International Society of Nephrology's Kidney Disease Data Center (ISN-KDDC) aimed to assess the prevalence and awareness of chronic kidney disease and its risk factors, and to investigate the risk of cardiovascular disease, in countries of low and middle income.
Introduction
Chronic kidney disease is an important cause of global morbidity and mortality. 1, 2 In the 2013 Global Burden of Disease study, 956 200 people were estimated to have died from chronic kidney disease, a 134% increase from 1990, one of the largest rises among the top causes of death. 1 Furthermore, even in the early stages of chronic kidney disease, the risk of fatal and non-fatal cardiovascular events attributable directly to renal disease rises substantially. 3 Thus, kidney disease should be a global public health priority, particularly because, worldwide, more than 1·4 million individuals with end-stage renal disease are estimated to receive renal replacement therapy with dialysis or transplantation, with 8% annual growth. 4 A steep increase in cases of hypertension, diabetes, and other diseases that are risk factors for chronic kidney disease is also driving growth in prevalence of chronic kidney disease, putting enormous pressure on health-care resources. 5 High-quality screening programmes in high-income countries, including the USA, 6 Norway, 7 the Netherlands, 8 and Australia, 9 have shown the prevalence of chronic kidney disease in the general adult population is 10-13%. However, for many low-income and middle-income countries and regions, data for epidemiological features of chronic kidney disease are scarce or even missing 10 because of an absence of resources, inadequate data collection methods, and low awareness of the disorder. Moreover, in these diff erent settings, the primary causes of chronic kidney disease vary, and kidney disease might not be contained entirely within the envelope of diabetes and hypertension. Indeed, in developing countries, up to 40% of individuals whose chronic kidney disease is identifi ed in screening programmes do not have diabetes or cardiovascular disease; other risk factors such as HIV, 11 tuberculosis, and exposure to toxins 12 can cause chronic kidney disease, or the cause could remain unknown. 13 Therefore, careful assessment of epidemiological features of chronic kidney disease is needed, particularly for people living in countries of low and middle income who cannot aff ord the high costs of renal replacement therapy. 5 In 2005, the International Society of Nephrology (ISN) established programmes to build global capacity to screen populations to detect chronic kidney disease and its risk factors early, and for patients' management and followup. 14 To support data collection and analysis, ISN also funded the establishment of a global database, the Kidney Disease Data Center (KDDC), which provided the unique opportunity to gather information using a simple and uniform template. In the ISN-KDDC cross-sectional study, we aimed to estimate the prevalence of chronic kidney disease according to the latest KDIGO (Kidney Disease: Improving Global Outcomes) guidelines, 3 to investigate awareness of chronic kidney disease and its major risk factors, to assess risk factors associated with chronic kidney disease, and to calculate cardiovascular risk for screened populations.
Methods

Study population
We identifi ed adult cohorts in the KDDC database from 12 low-income and middle-income countries: Bangladesh, Bolivia, Bosnia and Herzegovina, China, Egypt, Georgia, India, Iran, Moldova, Mongolia, Nepal, and Nigeria. Almost all cohorts, with the exception of the Iranian cohort, included participants from the ISN programme on Detection and Management of Chronic Kidney Disease, Hypertension, Diabetes and Cardiovascular Disease in Developing Countries (KHDC).
14 KHDC guidelines provide a template for setting up early detection and intervention programmes
Research in context
Evidence before this study Several systematic reviews have been done to assess prevalence of chronic kidney disease, and in the 2013 Global Burden of Disease Study, mortality and morbidity from chronic kidney disease was estimated. To retrieve the most representative examples of screening programmes done in randomly selected populations or community settings, particularly low-income and middle-income countries, we did a non-systematic search of PubMed with the keywords "chronic kidney disease (community OR random) screening" and "chronic kidney disease awareness", and we searched manually through the recent content of relevant journals, up to July, 2015. In 2013, 956 200 deaths globally were attributed directly to chronic kidney disease, one of the highest increases in the past two decades. In several (mainly developed) countries, screening programmes detected a high prevalence of chronic kidney disease and low awareness. Criteria for chronic kidney disease and its components varied substantially between some of these screening programmes, and most were done with diff erent methods, developed by local researchers. The latest KDIGO (Kidney Disease: Improving Global Outcomes) guidelines standardised the classifi cation and prognosis of chronic kidney disease based on glomerular fi ltration rate (GFR) and albuminuria categories.
Added value of this study
Our cross-sectional data were obtained from screening programmes done on behalf of the International Society of Nephrology (ISN), across diff erent populations from low-income and middle-income countries, but using a uniform process and defi nition of chronic kidney disease. Decreased estimated GFR (eGFR) and increased albuminuria, and the resulting positive screening for prevalence of chronic kidney disease, are common in the general population of countries of low and middle income. Our applied screening method allowed estimation of low awareness, not only of chronic kidney disease but also of hypertension and diabetes. Moreover, a substantial proportion of individuals with known diseases did not take drugs, indicating poor access to basic treatment. Our data confi rmed an association between a positive screening test for chronic kidney disease and hypertension, diabetes, obesity, and high amounts in serum of cholesterol. We noted an incremental increase and cumulative eff ect of reduced eGFR and increased albuminuria on the Framingham risk score of developing cardiovascular disease within the next 10 years, but this risk was substantially underestimated in almost all patients with chronic kidney disease.
Implications of all the available evidence
Current recommendations in developed countries do not encourage screening for chronic kidney disease in the general population. However, in countries of low and middle income, we advocate screening programmes with confi rmatory testing as a unique method for detecting chronic kidney disease and other non-communicable diseases, with subsequent prevention, follow-up, and treatment. Further cost-eff ectiveness analyses should quantify the benefi t of such programmes for limitation of morbidity and mortality related to renal and cardiovascular complications. The epidemiology of chronic kidney disease has to be studied worldwide, and the ready-to-use method developed by ISN could help to achieve this important goal.
in developing countries based on specifi c needs, organisation facilities, and economic imperatives of each country. Volunteer bias was not handled in the KHDC-based screenings.
General population cohorts in the KDDC database (from KHDC-based programmes) were from eastern Asia (China, 18 ). In Bangladesh, high-risk individuals were identifi ed at the fi rst screening interview; in Egypt, those at high risk were fi rst-degree relatives of patients treated for chronic kidney disease with known microalbuminuria; in Bosnia and Herzegovina, high-risk individuals were inhabitants of Balkan endemic nephropathy areas, refugee camps, or gypsy communities; and in Georgia, those at high risk were people at risk of noncommunicable diseases diagnosed in university hospitals.
We judged participants eligible for our study if they were aged 18 years or older and had complete data for calculation of estimated glomerular fi ltration rate (eGFR) and for assessment of albuminuria. All KHDC-based programmes included in this study, and the one from Iran, have been approved by the ethics committees of local hospitals (or equivalent when available), and written or oral consent was obtained from participants.
Procedures
Questionnaires based on the KHDC template comprise self-reported information on sociodemographic factors (date of birth, sex, marital status, ethnic origin, level of education, and work), lifestyle (smoking, alcohol consumption, physical activity, and fruit and vegetable consumption), and medical history (chronic kidney disease, hypertension, diabetes, and cardiovascular disease), and we included these data when available. We coded data from the non-KHDC programme 19 in the same format as the KHDC template then imported it into the ISN-KDDC study database. We categorised ethnic origin as eastern or southern Asian, black African, white, and other-a group that included Hispanic and indigenous together.
For more than 85% of participants, measurement of serum creatinine was possible, in addition to dipstick testing for albuminuria or proteinuria; furthermore, for a smaller subset (26%), the albumin-to-creatinine ratio (ACR) or protein-to-creatinine ratio was also available. We calculated eGFR (in mL/min per 1·73 m²) with the CKD-EPI equation, 21 based on serum creatinine, age, sex, and a two-level racial variable (black vs other). We defi ned eGFR categories as: G1, normal or high (≥90 mL/min per 1·73 m²); G2, mildly decreased (60-89 mL/min per 1·73 m²); G3a, mildly to moderately decreased (45-59 mL/min per 1·73 m²); G3b, moderately to severely decreased (30-44 mL/min per 1·73 m²); G4, severely decreased (15-29 mL/min per 1·73 m²) and G5, kidney failure (<15 mL/min per 1·73 m²). 3 We assessed albuminuria as ACR approximate equivalent, 3, 22 using an algorithm that relies on ACR, protein-to-creatinine ratio, and protein dipstick, strictly in this order. We defi ned albuminuria categories as: A1 (normal to mildly increased) for ACR less than 30 mg/g, protein-to- 
KHDC-based programmes
General population cohorts Eastern Asia
• China (n=10 091) 15 • Mongolia (n=1082) 15 Southern Asia • India (n=3201) 16 • Nepal (n=21 809) 15 creatinine ratio less than 150 mg/g, or protein dipstickto +/-; A2 (moderately increased) for ACR 30 mg/g to less than 300 mg/g, protein-to-creatinine ratio 150 mg/g to less than 500 mg/g, or protein dipstick 1+; and A3 (severely increased) for ACR 300 mg/g or higher, proteinto-creatinine ratio 500 mg/g or higher, or protein dipstick 2+ or higher. We defi ned chronic kidney disease according to KDIGO guidelines 3 as either decreased eGFR (<60 mL/min per 1·73 m²) or albuminuria (ACR approximate equivalent >30 mg/g).
In subsets of participants who self-reported information about chronic kidney disease, hypertension, diabetes, and related treatments, we calculated the prevalence of awareness of the disease or treatment by dividing the number of people who self-reported the disease or treatment by the number who were classifi ed as having the disease or taking the treatment, according to objective criteria. We defi ned hypertension as: systolic blood pressure of 140 mm Hg or higher, diastolic blood pressure of 90 mm Hg or higher, or both; 23 use of antihypertensive drugs; or both of these. We defi ned diabetes as: fasting glucose of 7·0 mmol/L or higher; glycated haemoglobin of 6·5% or higher (48 mmol/mol); or use of antidiabetes drugs. We defi ned obesity as a body-mass index (BMI) of 27·5 kg/m² or higher for Asian populations 24 and 30 kg/m² or higher for all other populations. 25 We defi ned hypercholesterolaemia as total cholesterol of 6·0 mmol/L or higher in individuals without previous cardiovascular disease or 5·0 mmol/L or higher in those with previous cardiovascular disease. 22 For individuals who did not self-report cardiovascular disease (95%), we assessed the risk of developing this disorder within the next 10 years with the Framingham risk score, 26 a model that has achieved good results nationally and internationally. 27, 28 Cholesterol could be measured in a small subset of participants (53%); thus, we chose the simpler risk prediction model based on nonlaboratory predictors, incorporating BMI instead of total and HDL cholesterol. 26 This model assumes sex-specifi c coeffi cients for the probability of the individual developing cardiovascular disease within the next 10 years, based on age, diabetes, and smoking status, treated or untreated
Total (n=75 058)
General population (n=70 774) High-risk population (n=4284) 
Systolic blood pressure (mm Hg) 121 (18) 120 (17) 135 (24) Diastolic blood pressure (mm Hg) 78 (11) 78 (11) 84 (12) Mean arterial pressure (mm Hg) 93 (12) 92 (12) 101 (15) Fasting blood glucose (mmol/L) 5·1 (2·0), n=38 630 5·1 (2·0), n=34 943 hypertension, and BMI. We stratifi ed the 10-year risk of developing cardiovascular disease into three categories, low (<10%), medium (10% to <20%), and high (≥20%), 28 irrespective of existing chronic kidney disease or a related risk factors disorder.
Statistical analysis
We did not impute missing values into the study database or do case-wise deletion; therefore, the total number of participants diff ered by variable of interest. We tabulated descriptive statistics by count or percentage and used 95% CIs for categorical variables and either mean and SD or median and IQR (when appropriate), for continuous data. To investigate the possible association between risk factors and chronic kidney disease in the general population cohorts, we used univariable and multiple logistic regression. The predictors we included in the multiple logistic regression models were dichotomous risk factors for kidney damage (hypertension, diabetes, obesity, hypercholesterolaemia), cohort, and their interaction. We further adjusted the above models by age (change by 10 years) and sex. We judged p less than 0·05 signifi cant. We did all statistical analyses with R.
Role of the funding source
The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all data in the study and had fi nal responsibility for the decision to submit for publication. Figure 1 shows the process for selection of cohorts for the ISN-KDDC study. After exclusion of non-eligible records, 75 058 participants were included; 70 774 (94%) study participants were from seven general population cohorts and one healthy population cohort (Iran 19 ) and the remaining 4284 (6%) individuals were from four high-risk population cohorts. Sociodemographic and clinical characteristics of the participants are listed in table 1. Mean age was 44·5 years (SD 13·8) and 46 664 (62%) participants were men. 8168 (11%) individuals were from eastern Asia and 25 757 (34%) were from southern Asia; the ethnic origin of 1934 (3%) participants was black African and 35 793 (48%) people were white. Participants in general population cohorts were younger, more likely to be men, more educated, and less active smokers than were individuals in high-risk population cohorts. The screened general population also had lower blood pressure, a higher eGFR, and a lower prevalence of albuminuria (table 1) . No prominent sex diff erences were recorded, except that men were more educated, more frequently employed, and more likely to be active smokers compared with women, both in general and in high-risk cohorts (appendix pp 1, 2). Figure 2 shows the prevalence of chronic kidney disease in all 12 countries of low and middle income included in the ISN-KDDC study, and table 2 presents prevalence data adjusted by country, ethnic origin, and sex. In general population cohorts, the prevalence of chronic kidney disease was 14·3% (95% CI 14·0-14·5), with a prominent diff erence by ethnic origin. Women had a higher prevalence of chronic kidney disease than did men. In screened general populations, the overall prevalence of decreased eGFR (<60 mL/min per 1·73 m²) was 9·8% (95% CI 9·6-10·0) and of albuminuria was 5·5% (5·4-5·7). However, in general population cohorts from China, Mongolia, India, Moldova, and Bolivia, the prevalence of albuminuria was higher than the prevalence of decreased eGFR. In high-risk populations, the overall prevalence of chronic kidney disease was 36·1% (95% CI 34·7-37·6), with albuminuria having a greater eff ect than in general populations, with a prevalence of 32·6% (31·2-34·0); the prevalence of decreased eGFR was 8·3% (7·5-9·1; table 2). The overall prevalence of chronic kidney disease in high-risk cohorts was greater in men than in women. According to the KDIGO classifi cation, in the general population, fewer than 1% of individuals had severely increased albuminuria (category A3), and among those defi ned as having albuminuria (categories A2 and A3), one in fi ve participants had decreased eGFR (fi gure 3A). However, in high-risk populations, severely increased albuminuria (category A3) was detected in 3% of patients, and among those with increased albuminuria (categories A2 and A3) every seventh patient had decreased eGFR (fi gure 3B). The appendix (pp 4-9) shows the prevalence of chronic kidney disease in general population cohorts by world subregion.
Results
Awareness of chronic kidney disease was very low in both the general and high-risk cohorts: 409 (6%) of 6631 individuals in general populations and Several risk factors were associated with chronic kidney disease in the general population cohorts, at overall study population level or adjusted by cohort, and adjusted for cohort, age, and sex (table 3). In multiple logistic regression analyses, hypertension, diabetes, obesity, and high cholesterol were all associated independently with chronic kidney disease (overall, and for almost all regions). Overall, the odds of detecting chronic kidney disease were increased signifi cantly in individuals with hypertension (adjusted odds ratio 1·68, 95% CI 1·60-1·76), diabetes (1·75, 1·62-1·89), obesity (1·07, 1·01-1·14), and high serum cholesterol (1·22, 1·13-1·31). Data for the prevalence of risk factors for chronic kidney disease in individuals in the general population cohort who have chronic kidney disease are presented in the appendix (p 3).
In the general population cohort (n=67 009), 50 033 (75%) individuals were at low risk, 10 587 (16%) were at medium risk, and 6389 (10%) were at high risk of developing cardiovascular disease in the next 10 years. In the high-risk population cohort (n=4250), 2084 (49%) participants were at low risk, 770 (18%) were at medium risk, and 1396 (33%) were at high risk. Figure 5 shows the proportion of the population at high risk of developing cardiovascular disease in the next 10 years, by eGFR and albuminuria categories. Individuals in a higher category of albuminuria (A2 and A3) or decreased eGFR (G3a to G5) had a striking increase in 10-year risk, and the risk was even higher for individuals with both markers of kidney damage and dysfunction. Prevalence of chronic kidney disease by eGFR and albuminuria categories, overall and stratifi ed by sex Data are %. Chronic kidney disease-related risk defi ned as: green, low risk (if no other markers of kidney disease, no chronic kidney disease); yellow, moderately increased risk; orange, high risk; red, very high risk. 3 eGFR was calculated with the CKD-EPI equation: 21 G1, normal or high (≥90 mL/min per 1·73 m²); G2, mildly decreased (60-89 mL/min per 1·73 m²); G3a, mildly to moderately decreased (45-59 mL/min per 1·73 m²); G3b, moderately to severely decreased (30-44 mL/min per 1·73 m²); G4, severely decreased (15-29 mL/min per 1·73 m²) and G5, kidney failure (<15 mL/min per 1·73 m²). Albuminuria categories were defi ned as ACR approximate equivalent: A1, normal to mildly increased (ACR <30 mg/g); A2, moderately increased (ACR ≥30 mg/g to <300 mg/g); A3, severely increased (ACR ≥300 mg/g). ACR=albumin-to-creatinine ratio. eGFR=estimated glomerular fi ltration rate. 
Discussion
The fi ndings of the ISN-KDDC study are estimates for the prevalence of chronic kidney disease in populations of 12 low-income and middle-income countries in six regions of the world belonging to the ISN-KHDC and affi liated programmes. In the general population, the overall prevalence of chronic kidney disease was 14·3%, ranging from 5·5% in Bolivia to 29·9% in China. The mean prevalence of chronic kidney disease across all 12 countries was similar to the fi gure of 10-13% recorded by high-quality screening programmes in high-income countries. 6, 29 The specifi c features of the studied population could account for the variability in prevalence of chronic kidney disease we noted in the general cohorts. One of the lowest values for prevalence of chronic kidney disease was recorded in predominantly healthy, young (mean age 44 years), male taxi drivers in Iran, 19 whereas the highest prevalence was detected in China, where participants were older (mean age 53 years), 30% had elevated blood pressure, and 6% had diabetes. 15 Moreover, we recorded diff erences in ethnic origin, with a much lower prevalence of chronic kidney disease in white populations compared with people from Asian and black African backgrounds, which could be related to the known eff ect of ethnic origin on development of chronic kidney disease. 30 Nevertheless, it should be taken into account that the main objective of the ISN KHDC-based screening programmes, 14 established in 2005, was not to estimate the true prevalence of chronic kidney disease by repeat testing, as recommended by KDIGO guidelines published in 2012, 3 but to identify individuals at risk of or with kidney disease and to include them in follow-up programmes aimed at limiting morbidity and mortality related to complications of renal and cardiovascular disease in countries of low and middle income. Moreover, these ISN programmes provided an integrated view on the assessment of non-communicable diseases, which included detection of kidney abnormalities in the context of a wide range of risk factors and chronic diseases.
Screening for chronic kidney disease in high-risk populations (people with diabetes or hypertension, or who are older than 60 years) is recommended by the latest KDIGO guidelines 3 and most, 31 but not all, 32 costeff ectiveness studies. Conversely, screening for chronic kidney disease in the general population is not recommended by the US Preventive Task Force 33 because of the absence of high-quality data that can forecast its eff ectiveness in preventing complications. However, evidence shows that screening for chronic kidney disease Figure 4 : Awareness of chronic kidney disease by eGFR and albuminuria categories, overall and stratifi ed by sex Data are %. Chronic kidney disease-related risk defi ned as: green, low risk (if no other markers of kidney disease, no chronic kidney disease); yellow, moderately increased risk; orange, high risk; red, very high risk. 3 eGFR was calculated with the CKD-EPI equation: 21 G1, normal or high (≥90 mL/min per 1·73 m²); G2, mildly decreased (60-89 mL/min per 1·73 m²); G3a, mildly to moderately decreased (45-59 mL/min per 1·73 m²); G3b, moderately to severely decreased (30-44 mL/min per 1·73 m²); G4, severely decreased (15-29 mL/min per 1·73 m²) and G5, kidney failure (<15 mL/min per 1·73 m²). Albuminuria categories were defi ned as ACR approximate equivalent: A1, normal to mildly increased (ACR <30 mg/g); A2, moderately increased (ACR ≥30 mg/g to <300 mg/g); A3, severely increased (ACR ≥300 mg/g). ACR=albumin-to-creatinine ratio. eGFR=estimated glomerular fi ltration rate. NA=no data available. in the general population is plausible even for healthy individuals older than 50 years when done once every 10 years, which strikingly increases its cost-eff ectiveness. 34 Almost all recommendations-both for and against screening for chronic kidney disease-are based on data from the developed world. Although our study is not a cost-eff ectiveness analysis, our data provide important insights into the usefulness of screening for chronic kidney disease and its risk factors, both in general population and high-risk cohorts in countries of low and middle income. In particular, we found that in screened individuals, awareness of chronic kidney disease, hypertension, or diabetes was low: more than 90% of individuals did not know they had chronic kidney disease, almost every second screened patient did not know about his or her hypertension, and close to every third screened individual was unaware of his or her diabetes. These fi ndings parallel those of a large-scale screening programme in Brazil, 35 where more than four-fi fths of individuals with detected proteinuria were unaware of chronic kidney disease and roughly a quarter of the screened population with recorded high blood pressure did not know they had hypertension. In India, 36 only 2% of screened participants diagnosed with chronic kidney disease had a self-reported history of kidney disease, and in China, 29 a third of the rural and two-thirds of the urban population were unaware of their diabetes.
Our estimated awareness of chronic kidney disease (6% and 10%, for general and high-risk population cohorts, respectively) in low-income and middle-income countries seems comparable with data from developed countries. In US Kidney Early Evaluation Program (KEEP) screening programmes, the prevalence of patients aware of their existing chronic kidney disease was 7% 37 or 9%. 38 However, in a smaller cohort of KEEP participants with presumed chronic kidney disease, based on one measurement of renal function, awareness of chronic kidney disease was higher, up to 23%. 39 Furthermore, our study highlights that, in general populations, almost half of patients with high blood pressure did not take antihypertensive drugs and a third of people known to have diabetes did not receive antidiabetes drugs, which indicates that, in countries of low and middle income, a substantial number of patients have no access to appropriate treatment, even though both diabetes and hypertension are major risk factors for development and progression of chronic kidney disease, 
Odds ratios are for prediction of chronic kidney disease. NA=no data available in the subset for the corresponding predictor. *Univariable logistic regression included risk factor only. †Multiple logistic regression included risk factor, cohort, and risk factor:cohort interaction. ‡Multiple logistic regression included risk factor, age, and sex. §Multiple logistic regression included risk factor, age, sex, cohort, and risk factor:cohort interaction. and for complications and mortality from chronic kidney disease. 40, 41 Indeed, our analysis confi rmed the increased odds of detecting chronic kidney disease in patients with elevated blood pressure, diabetes, obesity, and high amounts of cholesterol in serum. In a subset of patients, we also detected a high prevalence of smoking, in either general (22%) or high-risk (34%) population cohorts, which is known as one of the risk factors for development of chronic kidney disease, not only during adult life 42 but also via epigenetic modifi cation and mitochondrial dysfunction during fetal programming. 43 According to the latest nephrology 44 and cardiology 40, 41 guidelines, all people with chronic kidney disease should be judged at high risk of complications from chronic kidney disease. However, no markers of chronic kidney disease (eg, decreased eGFR and increased albuminuria) are included in risk scores for cardiovascular disease, including the Framingham risk score-the non-laboratorybased version of which 26 we used to calculate the 10-year risk for developing cardiovascular disease in our study. Nevertheless, we reported an incremental increase in cumulative eff ect of reduced eGFR and increased albuminuria on the Framingham risk score, but the risk was substantially underestimated for most patients with chronic kidney disease. 35% of individuals in eGFR category 3B, and 20% and 31% of those in albuminuria category A2 and A3, respectively, would have been recognised by the Framingham risk score as being at high risk of cardiovascular disease, whereas all these patients are classifi ed as high risk by KDIGO guidelines. 3 These fi ndings suggest that timely recognition of chronic kidney disease could provide additional key information to appropriately estimate risk of cardiovascular disease in screened individuals in general populations in low-income and middle-income countries.
Our study has several limitations. First, individuals were screened based on convenience sampling with active referral from advertisements, or on specifi c geographical areas; thus, participants were not randomly selected from the whole population. Therefore, we cannot infer per country representativeness of renal abnormalities. This selection bias could have led us to overestimate the prevalence of chronic kidney disease in some regions, because we assessed people who volunteered to be tested. 45 Such bias has been proven in a US study comparing random selection in the NHANES study with active referral in the KEEP study, 37 in which the prevalence of chronic kidney disease was 13·1% and 28·7%, respectively. Similarly, in our screening programme in India, the prevalence of chronic kidney disease was 16·8%, but in another study in which random multistage cluster sampling was used, 36 prevalence was only 7·5%. Second, laboratory methods for measurement of creatinine were not standardised, which could introduce bias both for comparison of the prevalence of low eGFR between study sites and for adequate calculation of eGFR with the CKD-EPI . 26 High risk defi ned as a probability greater than 20%. eGFR was calculated with the CKD-EPI equation: 21 G1, normal or high (≥90 mL/min per 1·73 m²); G2, mildly decreased (60-89 mL/min per 1·73 m²); G3a, mildly to moderately decreased (45-59 mL/min per 1·73 m²); G3b, moderately to severely decreased (30-44 mL/min per 1·73 m²); G4, severely decreased (15-29 mL/min per 1·73 m²) and G5, kidney failure (<15 mL/min per 1·73 m²). Albuminuria categories were defi ned as ACR approximate equivalent: A1, normal to mildly increased (ACR <30 mg/g); A2, moderately increased (ACR ≥30 mg/g to <300 mg/g); A3, severely increased (ACR ≥300 mg/g). ACR=albumin-to-creatinine ratio. eGFR=estimated glomerular fi ltration rate.
formula, 21 which assumes creatinine standardisation (with a costly reference standard that is unaff ordable for most countries of low and middle income). However, in every country of low and middle income, creatinine measurement was calibrated according to manufacturer guidelines, which should have prevented major bias. Third, in most individuals, determinants of chronic kidney disease were based on one measurement of creatinine in serum and albuminuria, which could have contributed to overdiagnosis of chronic kidney disease in some screened individuals with transient changes in these variables. This approach is widespread in published literature on the epidemiology of chronic kidney disease: urinalysis and measurement of serum creatinine to calculate eGFR was done only once in studies of the prevalence of chronic kidney disease in the general population of high-income European countries [46] [47] [48] and the USA 39, 49 and in nationally representative screening for chronic kidney disease in China. 29 Although at the population level, one-time measurement of markers of chronic kidney disease is common and could be acceptable for estimation of prevalence, on the individual patient level, obligatory confi rmation of initial abnormalities should be done. To better discriminate the management strategy at population and individual levels, fi ndings obtained during screening-in which one calculation for eGFR and one evaluation of urinalysis was done-could be described more precisely as the prevalence of a positive screening test for chronic kidney disease, to which we refer in our analysis, while using the generally accepted term chronic kidney disease. Although there is a risk of false-positive results with this approach, 6 the main screening goal, particularly in countries of low and middle income, is to avoid falsenegative fi ndings. Therefore, in case of a positive result after initial detection, confi rmatory assessment should be set up before any intervention treatment is started or the patient is referred to a specialist. Finally, eGFR was calculated with the CKD-EPI equation, 21 which was developed for the US population, and although this formula includes a coeffi cient for ethnic origin, it could indicate eGFR imprecisely in multiethnic cohorts. Several diff erent coeffi cients have been proposed for Asian and black populations, 44, 50, 51 but currently they are neither widely recommended nor validated. 52 Moreover, in Chinese populations, the CKD-EPI two-level race equation was proven better than the Modifi cation of Diet in Renal Disease (MDRD) study equation and the CKD-EPI four-level race equation. 53 Thus, in our multiethnic cohort, we used the recommended 3 two-level race CKD-EPI equation.
Although formal comparison across diff erent populations is prevented by variable sampling strategies, our use of identical cutoff s for clinical and laboratory variables, the same screening protocol, one web-based database for data entry and centralised data monitoring in most cases, and inclusion of both urban and rural populations in screening and the programmes makes our analysis a unique opportunity to study the prevalence of chronic kidney disease and other noncommunicable diseases in countries of low and middle income. In conclusion, decreased eGFR and increased albuminuria-and the resulting prevalence of chronic kidney disease-are common in the general populations of countries of low and middle income. Our results not only suggest the feasibility of screening in poor-resource settings but also underline that, without local screening programmes, most individuals in these regions remain unaware of existing chronic kidney disease and its risk factors. This sparse knowledge precludes any appropriate prevention, follow-up, and treatment programmes for patients in need. In view of the major eff ect renal abnormalities have on cardiovascular disease, such screening programmes-complemented by sustainable management of patients who screen positive-should be implemented urgently with adjustments for local settings, along with generally strengthening the health-care workforce and making cheap drugs accessible to local populations. Prospective studies are warranted to quantify the potential benefi ts of this type of prevention strategy in countries of low and middle income.
